Merck Other Current Liab from 2010 to 2024

MRK Stock  USD 101.24  1.38  1.38%   
Merck Other Current Liabilities yearly trend continues to be quite stable with very little volatility. Other Current Liabilities may rise above about 18.3 B this year. From the period between 2010 and 2024, Merck, Other Current Liabilities regression line of its data series had standard deviation of  4,004,162,176 and standard deviation of  4,004,162,176. View All Fundamentals
 
Other Current Liabilities  
First Reported
1985-12-31
Previous Quarter
16.7 B
Current Value
18.5 B
Quarterly Volatility
5.6 B
 
Black Monday
 
Oil Shock
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Merck financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Merck's main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.8 B, Interest Expense of 1.2 B or Total Revenue of 32.4 B, as well as many indicators such as Price To Sales Ratio of 4.32, Dividend Yield of 0.0246 or PTB Ratio of 6.92. Merck financial statements analysis is a perfect complement when working with Merck Valuation or Volatility modules.
  
Check out the analysis of Merck Correlation against competitors.

Latest Merck's Other Current Liab Growth Pattern

Below is the plot of the Other Current Liab of Merck Company over the last few years. It is Merck's Other Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Merck's overall financial position and show how it may be relating to other accounts over time.
Other Current Liab10 Years Trend
Slightly volatile
   Other Current Liab   
       Timeline  

Merck Other Current Liab Regression Statistics

Arithmetic Mean13,363,713,333
Geometric Mean11,725,386,200
Coefficient Of Variation29.96
Mean Deviation2,445,888,889
Median13,829,000,000
Standard Deviation4,004,162,176
Sample Variance16033314.7T
Range17.5B
R-Value0.79
Mean Square Error6446945.5T
R-Squared0.63
Significance0.0004
Slope708,761,786
Total Sum of Squares224466406.2T

Merck Other Current Liab History

202418.3 B
202317.5 B
202216 B
202115.6 B
202014.7 B
201914.9 B
201813.6 B

About Merck Financial Statements

Merck investors utilize fundamental indicators, such as Other Current Liab, to predict how Merck Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Other Current Liabilities17.5 B18.3 B

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Merck Company is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Merck Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Merck Company Stock. Highlighted below are key reports to facilitate an investment decision about Merck Company Stock:
Check out the analysis of Merck Correlation against competitors.
You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Merck. If investors know Merck will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Merck listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.33)
Dividend Share
3.04
Earnings Share
4.78
Revenue Per Share
24.931
Quarterly Revenue Growth
0.044
The market value of Merck Company is measured differently than its book value, which is the value of Merck that is recorded on the company's balance sheet. Investors also form their own opinion of Merck's value that differs from its market value or its book value, called intrinsic value, which is Merck's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Merck's market value can be influenced by many factors that don't directly affect Merck's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Merck's value and its price as these two are different measures arrived at by different means. Investors typically determine if Merck is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Merck's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.